HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: Effects on VEGF, FGF-1, and SDF-1

BMC Biochemistry

Volumn 7, Issue , 2006, Pages

  Uchimura, Kenji ^a   Morimoto Tomita, Megumi ^a   Bistrup, Annette ^b   Li, Jessica ^a   Lyon, Malcolm ^c   Gallagher, John ^c   Werb, Zena ^a   Rosen, Steven D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Thios Pharmaceuticals   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR 1; GLUCOSAMINE; HEPARIN; HSULF 2 PROTEIN; PROTEIN; RECOMBINANT ENZYME; STROMAL CELL DERIVED FACTOR 1; SULFATE; UNCLASSIFIED DRUG; VASCULOTROPIN; ALPHA CHEMOKINE; BETA CHEMOKINE; BOVINE SERUM ALBUMIN; CCL21 PROTEIN, HUMAN; CXCL12 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE; HYBRID PROTEIN; INTERLEUKIN 8; SECONDARY LYMPHOID TISSUE CHEMOKINE; SULF2 PROTEIN, HUMAN; SULFOTRANSFERASE; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA MODIFICATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMOBILIZATION; MOLECULAR CLONING; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REPRODUCIBILITY; SULFATION; VALIDATION PROCESS; ADENOCARCINOMA; BREAST TUMOR; CHEMISTRY; CULTURE MEDIUM; ENZYMOLOGY; FEMALE; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

MINK CELL FOCUS-FORMING VIRUS;

ADENOCARCINOMA; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOKINE CCL21; CHEMOKINE CXCL12; CHEMOKINES, CC; CHEMOKINES, CXC; CULTURE MEDIA, CONDITIONED; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HEPARITIN SULFATE; HUMANS; INTERLEUKIN-8; NEOPLASM PROTEINS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN, BOVINE; SULFOTRANSFERASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644657201     PISSN: 14712091     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-7-2     Document Type: Article

References (48)

1. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999, 68:729-777.
2. Esko JD, Lindahl U: Molecular diversity of heparan sulfate. J Clin Invest 2001, 108:169-173.
3. Ornitz DM: FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000, 22:108-112.
4. Nakato H, Kimata K: Heparan sulfate fine structure and specificity of proteoglycan functions. Biochim Biophys Acta 2002, 1573:312-318.
5. Esko JD, Selleck SB: Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002, 71:435-471.
6. Witt DP, Lander AD: Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 1994, 4:394-400.
7. Gallagher JT: Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001, 108:357-361.
8. Lindahl U, Kusche-Gullberg M, Kjellen L: Regulated diversity of heparan sulfate. J Biol Chem 1998, 273:24979-24982.
9. Powell AK, Yates EA, Fernig DG, Turnbull JE: Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 2004, 14:17R-30R.
10. Murphy KJ, Merry CL, Lyon M, Thompson JE, Roberts IS, Gallagher JT: A new model for the domain structure of heparan sulfate based on the novel specificity of K5 lyase. J Biol Chem 2004, 279:27239-27245.
11. Jayson GC, Vives C, Paraskeva C, Schofield K, Coutts J, Fleetwood A, Gallagher JT: Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. Int J Cancer 1999, 82:298-304.
12. Brickman YG, Ford MD, Gallagher JT, Nurcombe V, Bartlett PF, Turnbull JE: Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development. J Biol Chem 1998, 273:4350-4359.
13. Habuchi O: Diversity and functions of glycosaminoglycan sulfotransferases. Biochim Biophys Acta 2000, 1474:115-127.
14. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CPJ: Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 2001, 293:1663-1666.
15. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD: Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 2002, 277:49175-49185.
16. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CPJ: QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol 2003, 162:341-351.
17. Viviano BL, Paine-Saunders S, Gasiunas N, Gallagher J, Saunders S: Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin. J Biol Chem 2004, 279:5604-5611.
18. Ohto T, Uchida H, Yamazaki H, Keino-Masu K, Matsui A, Masu M: Identification of a novel nonlysosomal sulphatase expressed in the floor plate, choroid plexus and cartilage. Genes Cells 2002, 7:173-185.
19. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V: Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003, 278:23107-23117.
20. Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, Matthews TA, Nagorney DM, Cunningham JM, Smith DI, Greene EL, Shridhar V, Roberts LR: hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 2004, 126:231-248.
21. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith DI, Roberts LR, Shridhar V: HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 2004, 23:1439-1447.
22. Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, Emerson CPJ: QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci U S A 2004, 101:4833-4838.
23. Li J, Kleeff J, Abiatari I, Kayed H, Giese N, Felix K, Giese T, Buchler MW, Friess H: Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer 2005, 4:14.
24. Morimoto-Tomita M, Uchimura K, Rosen SD: Novel Extracellular Sulfatase: Potential Roles in Cancer. Trends in Glycoscience and Glycotechnology 2003, 15:159-164.
25. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, Werb Z, Rosen SD: Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 2005, 7:1001-1010.
26. Kamimura K, Fujise M, Villa F, Izumi S, Habuchi H, Kimata K, Nakato H: Drosophila heparan sulfate 6-O-sulfotransferase (dHS6ST) gene. Structure, expression, and function in the formation of the tracheal system. J Biol Chem 2001, 276:17014-17021.
27. Bink RJ, Habuchi H, Lele Z, Dolk E, Joore J, Rauch GJ, Geisler R, Wilson SW, den Hertog J, Kimata K, Zivkovic D: Heparan sulfate 6-o-sulfotransferase is essential for muscle development in zebrafish. J Biol Chem 2003, 278:31118-31127.
28. Kreuger J, Salmivirta M, Sturiale L, Gimenez-Gallego G, Lindahl U: Sequence analysis of heparan sulfate epitopes with graded affinities for fibroblast growth factors 1 and 2. J Biol Chem 2001, 276:30744-30752.
29. Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K: Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem 2004, 279:12346-12354.
30. Feyzi E, Lustig F, Fager G, Spillmann D, Lindahl U, Salmivirta M: Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain. J Biol Chem 1997, 272:5518-5524.
31. Ono K, Hattori H, Takeshita S, Kurita A, Ishihara M: Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology 1999, 9:705-711.
32. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT: Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 1994, 269:11216-11223.
33. Parthasarathy N, Goldberg IJ, Sivaram P, Mulloy B, Flory DM, Wagner WD: Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase. J Biol Chem 1994, 269:22391-22396.
34. Feyzi E, Trybala E, Bergstrom T, Lindahl U, Spillmann D: Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C. J Biol Chem 1997, 272:24850-24857.
35. Wang L, Brown JR, Varki A, Esko JD: Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002, 110:127-136.
36. Ishihara M: Structural requirements in heparin for binding and activation of FGF-1 and FGF-4 are different from that for FGF-2. Glycobiology 1994, 4:817-824.
37. Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT: Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 1992, 267:10337-10341.
38. Saad OM, Ebel H, Uchimura K, Rosen SD, Bertozzi CR, Leary JA: Compositional profiling of heparin/heparan sulfate using mass spectrometry: assay for specificity of a novel extracellular human endosulfatase. Glycobiology 2005, 15:818-826.
39. Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT: Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem 1998, 273:22936-22942.
40. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992, 267:26031-26037.
41. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA: A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996, 184:1101-1109.
42. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 2004, 35:233-245.
43. Christopherson KW, Hood AF, Travers JB, Ramsey H, Hromas RA: Endothelial induction of the T-cell chemokine CCL21 in T-cell autoimmune diseases. Blood 2003, 101:801-806.
44. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, Vlodavsky I: Heparanase as mediator of angiogenesis: mode of action. Faseb J 2001, 15:1661-1663.
45. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744.
46. Vlodavsky I, Friedmann Y: Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001, 108:341-347.
47. Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Aingorn H, Friedmann Y, Schirrmacher V, Mitrani E, Vlodavsky I: Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A 2002, 99:10031-10036.
48. Najjam S, Gibbs RV, Gordon MY, Rider CC: Characterization of human recombinant interleukin 2 binding to heparin and heparan sulfate using an ELISA approach. Cytokine 1997, 9:1013-1022.